Journal
ISCIENCE
Volume 24, Issue 9, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.isci.2021.103037
Keywords
-
Categories
Funding
- NIH [U01AI148118]
- Owens foundation
- National Cancer Institute [NIH R15CA182769, P20CA221731, P20CA221696]
- CPRIT [RP150656]
- NIAID, NIH [Wuhan-Hu-1, NR-52308]
- NIH/NCI [P30 CA016672]
- BD
- Intel
Ask authors/readers for more resources
The development of an intranasal subunit vaccine that induces mucosal immunity in the respiratory tract has been reported, demonstrating the potential to prevent infection establishment in individuals and disease transmission.
Despite remarkable progress in the development and authorization of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a need to validate vaccine platforms for broader application. The current intramuscular vaccines are designed to elicit systemic immunity without conferring mucosal immunity in the nasal compartment, which is the first barrier that SARS-CoV-2 virus breaches before dissemination to the lung. We report the development of an intranasal subunit vaccine that uses lyophilized spike protein and liposomal STING agonist as an adjuvant. This vaccine induces systemic neutralizing antibodies, IgA in the lung and nasal compartments, and T-cell responses in the lung of mice. Single-cell RNA sequencing confirmed the coordinated activation of T/B-cell responses in a germinal center-like manner within the nasal-associated lymphoid tissues, confirming its role as an inductive site to enable durable immunity. The ability to elicit immunity in the respiratory tract can prevent the establishment of infection in individuals and prevent disease transmission.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available